Fig. 5From: Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trialChanges in the dose of etelcalcetide during the study in each dose group. The doses were 25, 50, and ≥ 75 mg (n = 45). For patients with intact PTH levels within the management target at screening and at the end of the study, the same doses of vitamin D agent and calcium-based phosphate binder were selectedBack to article page